Compare Amylx Pharmaceuticals Inc (AMLX) vs Comcast Corporation (CMCSA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Comcast Corporation — how do they compare? Amylx Pharmaceuticals Inc trades at $17.3 (market cap $1.98B), while Comcast Corporation trades at $24.22 (market cap $84.20B). The key difference: Comcast Corporation is far larger — about 42.5× Amylx Pharmaceuticals Inc's market cap, and Comcast Corporation pays a 5.6% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | CMCSA | |
|---|---|---|
Market Cap | $1.98B | $84.20B |
Sector | Health | Media |
52-Week High | $18.70 | $33.81 |
52-Week Low | $7.64 | $22.32 |
Enterprise Value | $1.70B | $169.34B |
Dividend Yield | — | 5.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
CMCSA trades at $23.57, up 0.96% with strong fundamentals including a low P/E of 4.62 and net income margin of 15%. Recent earnings beats and a $2.14B acquisition of ITV's media unit signal strategic growth. Technicals are bearish with support at $23, while analyst consensus remains bullish with a $30.94 price target.
Outlook: Undervalued with robust cash flow and dividend yield, but weighed by bearish technicals and spin-off uncertainty. Key risks include integration challenges from acquisitions and competitive pressures in media and broadband sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Comcast Corporation
Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to roughly 61 million U.S. homes and businesses, or nearly half of the country. About 56% of the homes in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC broadcast network, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is the dominant television provider in the U.K. and has invested heavily in exclusive and proprietary content to build this position. The firm is also the largest pay-television provider in Italy and has a presence in Germany and Austria.
Read more on CMCSA →
